- Title
- Randomized Phase II Evaluation of Bevacizumab Versus Bevacizumab Plus Fosbretabulin in Recurrent Ovarian, Tubal, or Peritoneal Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study
- Creators
- Bradley J. Monk - University of ArizonaMichael W. Sill - Roswell Park Cancer InstituteJoan L. Walker - University of OklahomaChristopher J. Darus - Maine Medical CenterGregory Sutton - Washington University in St. LouisKrishnansu S. Tewari - University of California, IrvineLainie P. Martin - Fox Chase Cancer CenterJeanne M. Schilder - Indiana UniversityRobert L. Coleman - Gynecological Oncology & Reproductive MedicineJai Balkissoon - Pharmaceutical Product DevelopmentCarol Aghajanian - Memorial Sloan Kettering Cancer Center
- Publication Details
- Journal of clinical oncology, Vol.34(19), pp.2279-2286
- Publisher
- American Society of Clinical Oncology
- Identifiers
- 991005969008802656
- Academic Unit
- Obstetrics & Gynecology
- Language
- English
- Resource Type
- Journal article
Journal article
Randomized Phase II Evaluation of Bevacizumab Versus Bevacizumab Plus Fosbretabulin in Recurrent Ovarian, Tubal, or Peritoneal Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study
Journal of clinical oncology, Vol.34(19), pp.2279-2286
07/01/2016
PMCID: PMC4962710
PMID: 27217446
Related links
Metrics
1 Record Views